|
US6482932B1
(en)
*
|
1997-11-05 |
2002-11-19 |
Ribozyme Pharmaceuticals, Incorporated |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
|
US6617438B1
(en)
*
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
|
US6528640B1
(en)
*
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
|
US7179796B2
(en)
|
2000-01-18 |
2007-02-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
US20020055479A1
(en)
*
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
|
WO2003070983A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN KINASE C ALPHA (PKC-ALPHA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
EP1390472A4
(de)
*
|
2001-05-29 |
2004-11-17 |
Sirna Therapeutics Inc |
Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
|
|
WO2003034985A2
(en)
*
|
2001-10-22 |
2003-05-01 |
University Of Rochester |
Telomerase interference
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
AU2003215161A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
EP2108707A3
(de)
*
|
2002-05-17 |
2010-04-14 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Molekulare Identifizierung der Aspergillus-Species
|
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
|
US7618948B2
(en)
|
2002-11-26 |
2009-11-17 |
Medtronic, Inc. |
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
|
|
US7829694B2
(en)
*
|
2002-11-26 |
2010-11-09 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
|
US7605249B2
(en)
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
|
FR2848573B1
(fr)
*
|
2002-12-13 |
2005-04-08 |
Exonhit Therapeutics Sa |
Compositions et methodes pour la detection et le traitement de pathologies neurodegeneratives
|
|
US7994149B2
(en)
|
2003-02-03 |
2011-08-09 |
Medtronic, Inc. |
Method for treatment of Huntington's disease through intracranial delivery of sirna
|
|
US7846906B2
(en)
|
2003-02-28 |
2010-12-07 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
US7534775B2
(en)
*
|
2004-04-08 |
2009-05-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating cardiac contractility
|
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
WO2006064519A2
(en)
*
|
2004-12-14 |
2006-06-22 |
National Institute Of Immunology |
Dnazymes for inhibition of japanese encephalitis virus replication
|
|
AU2006222563A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
|
HUE037173T2
(hu)
|
2006-08-08 |
2018-08-28 |
Univ Bonn Rheinische Friedrich Wilhelms |
5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
|
|
US9375440B2
(en)
|
2006-11-03 |
2016-06-28 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2119783A1
(de)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
|
|
US9738680B2
(en)
|
2008-05-21 |
2017-08-22 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5′ triphosphate oligonucleotide with blunt end and uses thereof
|
|
JP2012524540A
(ja)
|
2009-04-24 |
2012-10-18 |
プロセンサ テクノロジーズ ビー．ブイ． |
Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド
|
|
EP2512491B1
(de)
|
2009-10-16 |
2017-10-11 |
Glaxo Group Limited |
Hbv-antisense-hemmer
|
|
CN103140582A
(zh)
|
2010-08-24 |
2013-06-05 |
默沙东公司 |
含有内部非核酸间隔子的单链RNAi试剂
|
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
|
MX2013005413A
(es)
|
2010-11-15 |
2014-02-27 |
Univ Ramot |
Analogos de dipeptidos para el tratamiento de afecciones asociadas con la formacion de fibrillas amiloides.
|
|
EP2508530A1
(de)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
|
|
US8658783B2
(en)
|
2011-04-13 |
2014-02-25 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
EP3816288A3
(de)
|
2011-04-21 |
2021-07-14 |
Glaxo Group Limited |
Modulation einer hepatitis-b-virus (hbv)-expression
|
|
EP2806900B1
(de)
|
2012-01-27 |
2021-12-15 |
BioMarin Technologies B.V. |
Rna-modulierende oligonukleotide mit verbesserten eigenschaften zur behandlung der duchenne- und becker-muskeldystrophie
|
|
WO2014017938A2
(en)
*
|
2012-07-27 |
2014-01-30 |
BIAL - PORTELA & Cª, S.A. |
Process for the synthesis of substituted urea compounds
|
|
EP2712870A1
(de)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
DE102015113038B3
(de)
*
|
2015-07-13 |
2017-01-19 |
Simone Kann |
Oligonucleotide und deren Verwendung
|
|
WO2019079195A1
(en)
*
|
2017-10-16 |
2019-04-25 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
GENETICALLY MODIFIED MESENCHYMAL STEM CELLS FOR USE IN CARDIOVASCULAR PROSTHESES
|
